LeonaBio, Inc. LONA
We are a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis ("ALS"), with the goal of improving patients' lives.
Following a review of potential therapeutic and business opportunities, we acquired rights to a promising late-stage asset, lasofoxifene, for the potential treatment of ESR1-mutated ("mESR1") metastatic breast cancer in December 2025. This late-stage program has generated promising clinical data and we believe it represents a unique and exciting opportunity to diversify our pipeline. We believe this program fits well with our later-stage clinical development experience, and complements our in-house asset, ATH-1105, a Phase-2 ready program for the potential treatment of ALS.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| R&D | $17.5M | $70.7M | $93.8M | $61.5M | $42.8M | $13.3M | $3.8M | — |
| SG&A | $16.7M | $26.1M | $33.3M | $32.6M | $21.2M | $6.7M | $1.7M | — |
| Total operating expenses | $102.3M | $100.9M | $125.5M | $104.0M | $64.0M | $20.0M | $5.4M | — |
| Operating income | -$102.3M | -$100.9M | -$125.5M | -$104.0M | -$64.0M | -$20.0M | -$5.4M | — |
| Interest expense | — | — | — | — | $3.0K | $367.0K | $346.0K | — |
| Pre-tax income | -$106.0M | — | — | — | — | -$20.0M | -$5.2M | — |
| Income tax | $0 | — | — | — | — | — | — | — |
| Net income | -$106.0M | -$97.0M | -$117.7M | -$95.6M | -$54.9M | -$20.0M | -$5.2M | — |
| EPS, basic | -24.70 | -25.19 | -3.09 | -2.53 | -1.49 | — | — | — |
| EPS, diluted | -24.70 | -25.19 | -3.09 | -2.53 | -1.49 | -1.67 | -1.45 | — |
| Shares, diluted (wtd. avg.) | $4.3M | $3.8M | $38.0M | $37.7M | $36.9M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $69.3M | $48.4M | $90.6M | $96.0M | $110.5M | $60.6M | $2.1M | — |
| Short-term investments | $19.1M | $2.8M | $56.8M | $104.4M | $143.2M | $124.1M | — | — |
| Total current assets | $89.5M | $54.8M | $154.7M | $207.5M | $260.8M | $192.3M | $2.2M | — |
| Property, plant and equipment | $1.5M | $2.4M | $3.4M | $4.1M | $3.8M | $2.6M | — | — |
| Total assets | $92.2M | $58.8M | $160.2M | $258.2M | $332.0M | $279.6M | $2.2M | — |
| Accounts payable | $4.6M | $319.0K | $129.0K | $2.5M | $567.0K | $1.2M | $421.0K | — |
| Total current liabilities | $47.5M | $13.1M | $28.8M | $21.4M | $9.3M | $4.4M | $1.3M | — |
| Total liabilities | $64.4M | $13.9M | $30.1M | $23.0M | $10.9M | $5.3M | $4.9M | — |
| Retained earnings | -$511.8M | -$406.1M | -$309.2M | -$191.5M | -$95.9M | -$41.0M | -$21.1M | — |
| Total equity | $27.8M | $44.8M | $130.2M | $235.1M | $321.1M | $274.3M | -$19.7M | -$14.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$45.7M | -$97.2M | -$100.8M | -$72.5M | -$43.1M | -$24.1M | -$3.7M | — |
| Depreciation and amortisation | $972.0K | $970.0K | $969.0K | $845.0K | $479.0K | $2.0K | $2.0K | — |
| Stock-based compensation | $6.1M | $11.0M | $10.6M | $10.6M | $4.6M | $633.0K | $253.0K | — |
| Capital expenditure | — | $33.0K | $304.0K | $1.1M | $1.6M | $2.3M | — | — |
| Investing cash flow | -$15.9M | $54.8M | $95.1M | $57.7M | -$4.1M | -$210.1M | $1.5M | — |
| Financing cash flow | $82.5M | $194.0K | $493.0K | $654.0K | $97.1M | $292.8M | $946.0K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-216742.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |